Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.29.15_SUPPL.6514PMID 28019977
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Investigational therapies targeting signal transducer and activator of transcription 3 for the treatment of cancer

  2015cites this paper
• Novel myelofibrosis treatment strategies: potential partners for combination therapies

  2014cites this paper
• Janus kinase inhibitors for the treatment of myeloproliferative neoplasms

  2014cites this paper
• Quality of Life in MPN Comes of Age as a Therapeutic Target

  2014cites this paper
• Jak-2 Positive Myeloproliferative Neoplasms

  2014cites this paper
• JAK inhibitors for myeloproliferative neoplasms

  2014cites this paper
• How I treat myelofibrosis.

  2014cites this paper
• Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies

  2014cites this paper
• The role of Janus kinase 2 (JAK2) in myeloproliferative neoplasms: therapeutic implications.

  2013cites this paper
• Comprehensive review of JAK inhibitors in myeloproliferative neoplasms

  2013cites this paper
• Pomalidomide and the growing role of immunomodulatory agents in the treatment of myelofibrosis

  2013cites this paper
• Novel therapies in the classical BCR–ABL-negative myeloproliferative neoplasms

  2013cites this paper
• Dysregulation of JAK-STAT pathway in hematological malignancies and JAK inhibitors for clinical application

  2013influential citation
• Therapy with JAK 1/2 inhibitors for myelofibrosis

  2013cites this paper
• Myelofibrosis: an update on current pharmacotherapy and future directions

  2013cites this paper
• Emerging targeted therapies in myelofibrosis

  2012cites this paper
• Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.

  2012cites this paper
• JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths.

  2012cites this paper
• The evolving treatment paradigm in myelofibrosis

  2012cites this paper
• JAK2 inhibitors and their impact in myeloproliferative neoplasms

  2012cites this paper
• Janus kinase inhibitors: jackpot or potluck?

  2012cites this paper
• New generation small-molecule inhibitors in myeloproliferative neoplasms

  2012cites this paper
• Pathology consultation on myeloproliferative neoplasms.

  2012cites this paper
• Breakthroughs in myeloproliferative neoplasms

  2012cites this paper
• Allogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitors.

  2012cites this paper
• Emerging drugs for myelofibrosis

  2012cites this paper
• A Critical Review of the Role and Limitations of JAK Inhibitors in Myelofibrosis Therapy

  2012cites this paper
• Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors

  2012cites this paper
• How I treat splenomegaly in myelofibrosis

  2011cites this paper
• Janus kinase inhibitors: an update on the progress and promise of targeted therapy in the myeloproliferative neoplasms

  2011cites this paper
• JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.

  2011cites this paper